Efficacy and Safety of Lianhua Qingke Tablets in the Treatment of Mild and Common-Type COVID-19: A Randomized, Controlled, Multicenter Clinical Study

Table 1

Baseline demographic data.

Variable	Treatment group; N = 72	Control group; N = 72	value
Age (y, x ± s)	49.56 ± 14.88	52.81 ± 14.83	0.1915
Males (N, %)	23 (31.94%)	24 (33.33%)	0.8589
Temperature (°C, x ± s)	37.14 ± 0.81	37.01 ± 0.83	0.2164
Respiratory rate (bpm, x ± s)	19.75 ± 2.45	19.60 ± 2.15	0.6329
Pulse (times/min, x ± s)	79.72 ± 10.21	76.90 ± 9.02	0.3402
Systolic pressure (mmHg, x ± s)	124.75 ± 16.30	127.61 ± 13.14	0.0847
Diastolic pressure (mmHg, x ± s)	79.88 ± 9.51	80.53 ± 10.29	0.3990
Routine blood test
Leukocyte count (N, x ± s)	5.09 ± 1.79	5.18 ± 1.50	0.5323
Neutrophil percentage (%, x ± s)	60.94 ± 12.46	61.22 ± 13.26	0.7064
Lymphocyte count (N, x ± s)	1.49 ± 0.60	1.49 ± 0.51	0.5987
Concomitant medications	56 (78.87%)	65 (90.28%)	0.0588

value, comparison between the treatment group and the control group.  < 0.05 indicates a significant difference.